As a result, further in vitro and in vivo studies are necessary to validate our findings, particularly those related to the activation of HDAC9 and NFATC1 in thymic carcinomas, before they can be applied in a clinical context. This evidence concerns the gene HDAC9 and thymic carcinoma.